T-DM1 Combined With CDK4/6 Inhibitor Ribociclib
NCT06481956
·
clinicaltrials.gov ↗
PHASE2
Phase
ENROLLING_BY_INVITATION
Status
40
Enrollment
OTHER
Sponsor class
Conditions
HER2-positive Advanced Breast Cancer
Interventions
DRUG:
Ribociclib Oral Tablet
Sponsor
Zheng Yabing